Evidence for the recognition of non-nucleotide antagonists within the transmembrane domains of the human P2Y1 receptor

Drug Development Research

Volumn 57, Issue 4, 2002, Pages 173-181

  Guo, Danping ^a   Von Kügelgen, Ivar ^a,b   Moro, Stefano ^a,c   Kim, Yong Chul ^a,d   Jacobson, Kenneth A ^a,e  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF PADOVA   (Italy)

^d Gwangju Institute of Science and Technology (GIST)   (South Korea)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Antagonists; G protein coupled receptors; Mutagenesis; Nucleotides; Phospholipase C

Indexed keywords

2 METHYLTHIOADENOSINE 5' DIPHOSPHATE; 6 (2' CHLOROPHENYLAZO)PYRIDOXAL ALPHA5 PHOSPHATE; 8,8' [CARBONYLBIS(IMINO 3,1 PHENYLENE)]BIS(1,3,5 NAPHTHALENE TRISULFATE); CIBACRON BLUE F3GA; G PROTEIN COUPLED RECEPTOR; INOSITOL PHOSPHATE; LYSINE; MRS 2210; NF 023; PHOSPHOLIPASE C; PURINE P2Y RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; PYRIDOXAL PHOSPHATE 6 AZOPHENYL 2',4' DISULFONIC ACID; SURAMIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL STRAIN COS7; CONTROLLED STUDY; DRUG BINDING SITE; DRUG RECEPTOR BINDING; LIGAND BINDING; MOLECULAR RECOGNITION; NONHUMAN; PROTEIN DOMAIN; RECEPTOR AFFINITY; SITE DIRECTED MUTAGENESIS;

EID: 0036997976     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10145     Document Type: Article

References (30)

1. Arunlakshana O, Schild HO. 1959. Some quantitative uses of drug antagonists. Br J Pharmacol 14:48-58.
2. 2Y purinoceptors. Br J Pharmacol 113:614-620.
3. Bültmann R, Wittenburg H, Pause B, G Kurz G, P Nickel P, Starke K. 1996. P2-purinoceptor antagonists: III Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by compounds related to suramin. Naunyn Schmiedeberǵs Arch Pharmacol 354:498-504.
4. 1 receptors. J Med Chem 41:183-190.
5. 2U-purinoceptors. Br J Pharmacol 118:704-710.
6. Colquhoun D. 1998. Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br J Pharmacol 125:924-947.
7. Erb L, Garrad R, Wang Y, Quinn T, Turner JT, Weisman GA. 1995. Site-directed mutagenesis of P2U purinoceptors: positively charged amino-acids in transmembrane helices 6 and 7 affect agonist potency and specificity. J Biol Chem 270:4185-4188.
8. 1-deficient mice. Nature Med 5:1199-1202.
9. Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden TK, Jacobson KA, Leff P, Williams M. 1994. Nomenclature and classification of purinoceptors. Pharmacol Rev 46:143-156.
10. Furchgott RF, 1972. The classification of adrenoceptors (adrenergic receptors) An evaluation from the standpoint of receptor theory In: Blaschko H, Muscholl E, editors. Handbook of experimental pharmacology, Vol 33. Berlin: Springer. p 283-335.
11. 3 adenosine receptor. J Biol Chem 277:19056-19063.
12. 1 receptor. FASEB J 13:A465.
13. Harden TK, Hawkins PT, Stephens L, Boyer JL, Downes P. 1988. Phosphoinositide hydrolysis by guanosine 5′-(ω-thio)triphosphate-activated phospholipase C of turkey erythrocyte membranes. Biochem J 252:583-593.
14. Jacobson KA, Hoffmann C, Kim YC, Camaioni E, Nandanan E, Jang SY, Guo DP, Ji XD, von Kügelgen I, Moro S, Ziganshin AU, Rychkov A, King BF, Brown SG, Wildman SS, Burnstock G, Boyer JL, Mohanram A, Harden TK. 1999. Molecular recognition in P2 receptors: Ligand development aided by molecular modeling and mutagenesis. In: Illes P, Zimmermann H, editors. Progress in brain research, Vol. 120. Amsterdam: Elsevier. p 119-132.
15. Jacobson KA, Jarvis MF, Williams M. 2002. Perspective: purine and pyrimidine (P2) receptors as drug targets. J Med Chem 45: 4057-4093.
16. 1 receptor. Mol Pharmacol 52:499-507.
17. Khakh BS, Burnstock G, Kennedy C, King BF, North RA, Seguela P, Voigt M, Humphrey PP. 2001. International union of pharmacology XXIV Current status of the nomenclature and properties of P2X receptors and their subunits. Pharmacol Rev 53:107-118.
18. Kim YC, Camaioni E, Ziganshin AU, Ji XD, King BF, Wildman SS, Rychkov A, Yoburn J, Kim H, Mohanram A, Harden TK, Boyer JL, Burnstock G, Jacobson KA. 1998. Synthesis and structure-activity relationships of pyridoxal-6-arylazo-5′-phosphate and phosphonate derivatives as P2 receptor antagonists. Drug Dev Res 45:52-66.
19. Lambrecht G. 1996. Design and pharmacology of selective P2-purinoceptor antagonists. J Auton Pharmacol 16:314-344.
20. Lambrecht G. 2000. Agonists and antagonists acting at P2X receptors: selectivity profiles and functional implications. Naunyn-Schmiedeberg's Arch Pharmacol 362:340-350.
21. Lambrecht G, Friebe T, Grimm U, Windscheif U, Bungardt E, Hildebrandt C, Bäumert HG, Spatz-Kümbel G, Mutschler E. 1992. PPADS, a novel functionally selective antagonist of P2 purinoceptor-mediated responses. Eur J Pharmacol 217:217-219.
22. 2X-receptors in the rabbit isolated ear artery. Br J Pharmacol 101:645-649.
23. 1 receptor-null mice. J Clin Invest 104:1731-1737.
24. 1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. J Med Chem 41:1456-1466.
25. Palmer RK, Boyer JL, Schachter JB, Nicholas RA, Harden TK. 1998. Agonist action of adenosine triphosphates at the human P2Y1 receptor. Mol Pharmacol 54:1118-1123.
26. Ralevic V, Burnstock G. 1998. Receptors for purines and pyrimidines. Pharmacol Rev 50:413-492.
27. 1 receptor to phospholipase C. Br J Pharmacol 122:1021-1024.
28. 1 cells. J Pharmacol Exp Ther 292:346-350.
29. van Rhee AM, Jacobson KA. 1996. Molecular architecture of G protein-coupled receptors. Drug Devel Res 37:1-38.
30. Waud DR, 1976. Analysis of dose-response relationships. In: Narahashi T, Bianchi CP, editors. Advances in general and cellular pharmacology. New York: Plenum Press. p 145-178.